Innovations In Systemic Treatments For Psoriasis | Andrew Blauvelt, Md, Mba | United States

Innovations in Systemic Treatments for Psoriasis | Andrew Blauvelt, MD, MBA | United States

International Psoriasis Council

The Psoriasis Pipeline: Upcoming New Systemic Drugs | Andrew Blauvelt, MD, MBA | United States

International Psoriasis Council

Considering Comorbidities in Treatment Planning | Andrew Blauvelt, MD, MBA | United States

International Psoriasis Council

Hot Psoriasis Topics: Single Cell RNA Sequencing | Andrew Blauvelt, MD, MBA | United States

International Psoriasis Council

Innovations in Topical Treatments for Psoriasis | Charles Lynde, MD, FRCPC, DABD, FCDA | Canada

International Psoriasis Council

Applying the Psoriasis Guidelines to Practice

Dermatology Education Foundation

Psoriasis: Which Drug for Which Patient?

Treatment of Psoriatic Disease

ClevelandClinicCME

How to KNOCK OUT Disease Memory | Andy Blauvelt, MD, MBA | United States

International Psoriasis Council

Trailer: In Conversation: A New Method of Classifying Psoriasis Severity from IPC

International Psoriasis Council

The Current State of Psoriasis Treatment with Targeted Therapy

Ch 1: In Conversation: A New Method of Classifying Psoriasis Severity

International Psoriasis Council

Ch 3: Communicating the strengths, limitations, and barriers to adoption of new consensus guidelines

International Psoriasis Council

Efficacy and safety of mirikizumab in psoriasis: OASIS-1, A. Blauvelt et al

British Journal of Dermatology

Biosimilars for psoriasis, A. Blauvelt et al

British Journal of Dermatology

Consider comorbidities when preparing patients for systemic psoriasis therapy

MDedge: news and insights for busy physicians

Psoriasis Flares

National Psoriasis Foundation

Psoriasis - Treatment Options

skinexpertstalk

Ch 2: Defining the new consensus on categorizing patients with psoriasis

International Psoriasis Council

Psoriatic Disease: Immunology and Treatment Targets, Part 1

Dermatology Education Foundation